Abstract | OBJECTIVE: EXPERIMENTAL DESIGN: In the absence of head-to-head trials, ITC was performed on patients with adenocarcinoma histology non-squamous NSCLC to compare the relative benefit of first-line therapies BCP vs. PC by hazard ratios (HR). Subsequently, these HRs were used in a decision-analytic Markov model with a lifelong time horizon to extrapolate the long-term effectiveness of the two treatments. RESULTS: ITC estimated HRs for the primary endpoints in the bevacizumab study E4599 showed that BCP treatment in non-squamous adenocarcinoma NSCLC patients resulted in a BCP HR of 0.82 versus PC. The long-term predictions from the Markov model yielded a mean survival of 1.48 years (95% CI 1.34, 1.62 years) (or 17.7 months) for BCP compared with 1.29 years (95% CI 1.16, 1.42 years) (or 15.4 months) for PC. CONCLUSIONS: Based on our decision analysis, triplet BCP targeted therapy in patients with advanced non-squamous adenocarcinoma NSCLC compared with doublet PC chemotherapy results in improved expected values for overall long-term survival. Therefore, from the efficacy perspective, bevacizumab in combination with platinum-based chemotherapy can be considered as the targeted therapy of choice for patients with advanced non-squamous adenocarcinoma NSCLC.
|
Authors | Mark J C Nuijten, Rick Aultman, Javier de Castro Carpeño, Alain Vergnenègre, Christos Chouaid, Stefan Walzer, Uwe Siebert |
Journal | Current medical research and opinion
(Curr Med Res Opin)
Vol. 27
Issue 11
Pg. 2193-201
(Nov 2011)
ISSN: 1473-4877 [Electronic] England |
PMID | 21970659
(Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Glutamates
- Pemetrexed
- Bevacizumab
- Guanine
- Carboplatin
- Paclitaxel
- Cisplatin
|
Topics |
- Adenocarcinoma
(drug therapy, mortality, pathology)
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bevacizumab
- Carboplatin
(administration & dosage, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality, pathology)
- Cisplatin
(administration & dosage, therapeutic use)
- Disease-Free Survival
- Glutamates
(administration & dosage, therapeutic use)
- Guanine
(administration & dosage, analogs & derivatives, therapeutic use)
- Humans
- Markov Chains
- Paclitaxel
(administration & dosage, therapeutic use)
- Pemetrexed
- Treatment Outcome
|